Lung Cancers Today
Advertisement
Clinicians hypothesize that the genetic mutation, known as RUFY1-RET fusion, caused resistance to lorlatinib.
Researchers evaluated if demographics, clinical characteristics, and outcomes varied between those with KRAS G12C and G12D.
The therapy is currently under evaluation in phase 1 and phase 2 trials.
A distributed clinical trial is analyzing diet and exercise patterns in young people with lung cancer.
The Prescription Drug User Fee Act action date is expected in the third quarter of 2025.
Dr. Liu unpacks the trial results, the recent approval, and the unique biomarker testing considerations for NRG1 fusions.
It is the "first and only neoadjuvant-only immuno-oncology therapy" to show a significant OS benefit in this setting.
A multicenter study that included 21,062 patients who were seen from 2009-2021 in South Korea provided key insights.
Christopher Seder, MD, discusses the database and how it can be used for research, quality improvement, and risk ...
The 12-member board will guide the guide the patient-driven organization’s research and strategic priorities.
The study is comparing ivonescimab plus platinum-based chemotherapy with tislelizumab plus platinum-based chemotherapy.
Mara B. Antonoff, MD, FACS, discusses what could be on the horizon for surgery in stage IV lung cancer.
The bispecific antibody, which recently received FDA accelerated approval, showed a response rate of 29% in NSCLC.
Dr. Merritt shares new thoracic surgery research insights for patient selection in sublobar resection for early-stage NSCLC.
The recommendation is based on results from the phase 3 ADRIATIC trial.
The study aims to confirm safety and efficacy findings from the phase 2 QUILT 3.055 trial.
The study is evaluating a prophylactic dermatologic regimen in patients receiving amivantamab plus lazertinib.
The CHMP positive opinion is supported by results from the phase 3 PALOMA-3 study.
Dr. Seder discusses the real-world study he presented at STS 2025, which addressed key questions about long-term outcomes.
Pending discussions with the FDA, officials say there are plans to submit for regulatory approval in the second half of 2025.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.